Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Marginal Zone Lymphoma
Related studies linked through entity extraction aliases.
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
- Status
- TERMINATED
- Phase
- PHASE1
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
- Status
- TERMINATED
- Phase
- PHASE2
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Imexon for Relapsed Follicular and Aggressive Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- N/A
Lenalidomide and R-CHOP in B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
- Status
- COMPLETED
- Phase
- PHASE3